We are live on ! Find out more
NKTR icon

Nektar Therapeutics

122 hedge funds and large institutions have $106M invested in Nektar Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 49 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,513% more call options, than puts

Call options by funds: $449K | Put options by funds: $8K

0.96% less ownership

Funds ownership: 62.5% → 61.54% (-0.96%)

2% less funds holding

Funds holding: 125 → 122 (-3)

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

26% less capital inflows, than outflows

Capital inflows: $11.3M | Capital outflows: $15.3M

59% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 49

Holders
122
Holders Change
-3
Holders Change %
-2.4%
% of All Funds
1.75%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
15
Increased
20
Reduced
49
Closed
18
Calls
$449​K
Puts
$8​K
Net Calls
+$441​K
Net Calls Change
+$438​K

NKTR Hedge Fund Activity: Q1 2024 in Review

122 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2024, worth a combined $106M — up 57% from $67.3M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of NKTR and 15 opened new positions — a net loss of 3 holders — while 49 trimmed existing stakes and 20 added.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $2.79M. The largest seller was GSA Capital Partners, cutting an estimated $2.28M.

  • 122 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2024, down from 125 in Q4 2023.
  • Funds reported $106M of Nektar Therapeutics stock for Q1 2024, up 57% quarter-over-quarter.
  • 15 funds opened new Nektar Therapeutics positions in Q1 2024 and 18 closed out, a net change of -3 holders.
  • The largest Nektar Therapeutics buyer in Q1 2024 was TCG Crossover Management, an estimated $2.79M added.
  • The largest Nektar Therapeutics seller in Q1 2024 was GSA Capital Partners, an estimated $2.28M sold.

Based on aggregated 13F filings for Q1 2024.